Emtricitabine: A novel nucleoside reverse transcriptase inhibitor

Drugs of Today

Volumn 41, Issue 4, 2005, Pages 241-252

  Molina, Jean Michel ^a   Cox, Sandra L ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b Medical Information Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMIVIRINE; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ALLERGIC REACTION; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ASTHENIA; CLINICAL TRIAL; COUGHING; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SAFETY; DRUG TOLERABILITY; FATTY LIVER; FOOD DRUG INTERACTION; GENE MUTATION; HEADACHE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LACTIC ACIDOSIS; MYALGIA; NAUSEA; NEUROPATHY; NONHUMAN; PAPULE; PARESTHESIA; PRURITUS; PUSTULE; RASH; REVIEW; URTICARIA; VIRUS REPLICATION; VOMITING;

ADULT; AREA UNDER CURVE; CELL LINE, TUMOR; CHILD; DEOXYCYTIDINE; DRUG RESISTANCE, VIRAL; HEPATITIS B; HIV INFECTIONS; HIV-1; HUMANS; METABOLIC CLEARANCE RATE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 22244451346     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.4.900219     Document Type: Review

References (35)

1. Gallant, J.E. The ideal nucleoside/nucleotide backbone. J Acquir Immune Defic Syndr 2004, 37 (Suppl. 1): S44-55.
2. Gilead Sciences. Emtriva prescribing information. Foster City, CA, USA, Sept 2004.
3. Feng, J.Y., Murakami, E., Zorca, S.M. et al. Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2′,3′-dideoxy-5-fluoro-3′-thiacytidine- triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob Agents Chemother 2004, 48: 1300-6.
4. Schinazi, R.F., McMillan, A., Cannon, D. et al. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 1992, 36: 2423-31.
5. Hazen, R., Lanier, E.R. Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type. J Acquir Immune Defic Syndr 2003, 32; 255-8.
6. Tisdale, M., Kemp, S.D., Parry, N.R., Larder, B.A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci 1993, 90: 5653-6.
7. Harris, J., Snow, A., Borroto-Esoda, K. et al. Emtricitabine therapy for hepatitis infection in HIV-1 patients co-infected with hepatitis B: Antiviral response and genotypic findings in antiretroviral treatment naive patients. 11th Conf Retroviruses Opportunistic Infections (Feb 8-11, San Francisco) 2004, Abstr. 836.
8. Rousseau, F., Fang, L., Sykes, A., Rigney, A., Mondou, E. Emtricitabine: antiviral efficacy and lack of development of resistance in patients treated 1 year for chronic hepatitis B virus infection parallel results in HIV infection. Antiviral Therapy 2001, 6(Suppl 1): 5.
9. Gish, R., Leung, N., Wang, C. et al. Antiviral activity, safety, and incidence of resistance in chronically infected hepatitis B patients (CHB) given once daily emtricitabine for 2 years. 53rd Ann Meeting Amer Soc Liver Dis (Nov 1-5, Boston) 2002: Abstr. 838.
10. Gish, R.G., Leung, N.W.Y., Wright, T.L. et al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002, 46: 1734-40.
11. Rousseau, F.S., Kahn, J.O., Thompson, M. et al. Prototype trial design for rapid dose selection of antiretroviral drugs: An example using emtricitabine (Coviracil). J Antimicrob Chemother 2001, 48: 507-13.
12. Rousseau, F.S., Wakeford, C., Mommeja-Marin, H. et al. Prospective randomized trial of emtricitabine vs. lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis 2003, 188: 1652-8.
13. Molina, J.M., Peytavin, G., Perusat, S. et al. Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). HIV Med 2004, 5: 99-104.
14. Wang, L.H., Begley, J., St. Claire III, R.L., Harris, J., Wakeford, C., Rousseau, F. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine supports its once daily dosing for the treatment of HIV infection. AIDS Research and Human Retroviruses 2004, 20: 1173-82.
15. Wang, L.H., Blum, M.R., Hui, J., Hulett, L., Chittick, G.E., Rousseau, F. Lack of significant pharmacokinetic interactions between emtricitabine and other nucleoside antivirals in healthy volunteers. 41st Interscience Conf Antimicrob Agents Chemother (Sept 22-25, Chicago) 2001, Abstr. A-505.
16. Wang, L.H., Wiznia, A.A., Rathore, M.H. et al. Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2004, 48: 183-191.
17. Molina, J.M., Ferchal, F., Rancinan, C. et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis 2000, 182: 599-602.
18. Furco, A. 5th Interscience Conference of Antimicribial agents and Chemotherapy (Oct, Chicago) 2004, Abstract.
19. Saag, M.S., Cahn, P., Raffi, F. et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients. JAMA 2004, 292: 180-9.
20. Gathe, J., Podzamczer, D., Johnson, M. et al. Once-daily vs. twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 48-week results. 11th Conf Retroviruses Opportunistic Infections (Feb 8-11, San Francisco) 2004, Abstr. 570.
21. Molina, J.M., Gathe, J., Lim, P.L. et al. Comprehensive resistance testing in antiretroviral-naive patients treated with once-daily lopinavir/ ritonavir plus tenofovir DF and emtricitabine: 48-week results from study 418. XV Int AIDS Conf (July 11-16, Bangkok) 2004, Abstr. WePeB5701.
22. Gazzard, B., Dejesus, E., Campo, R. et al. The combination of tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) has significantly greater response vs fixed dose zidovudine/ lamivudine (CBV) and EFV in antiretroviral naive patients: a 24-week preliminary analysis. 44th Interscience Conf Antimicrob Agents Chemother (Oct 30-Nov 2, Washington, D.C.) 2004, Abstr. H-1137C.
23. Molina, J.M., Journot, V., Morand-Joubert, L. et al. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: A randomized trial. J Infect Dis 2005, 191: 830-9.
24. Wakeford, C., Shen, G., Hulett, L., Quinn, J.B., Rousseau, F. Long-term efficacy and safety of emtricitabine in HIV+ adults switching from a lamivudine containing HAART regimen. 10th Conf Retroviruses and Opportunistic Infections (Feb 10-14, Boston) 2003, Abstr. 550.
25. Benson, C.A., van der Horst, C., Lamarca, A. et al. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS 2004, 18: 2269-76.
26. McKinney, R., Rodman, J., Rathore, M. et al. Extended follow-up and pharmacokinetics for once daily emtricitabine, didanosine, and efavirenz for antiretroviral naive children and adolescents. 11th Conf Retroviruses Opportunistic Infections (Feb 8-11, San Francisco) 2004, Abstr. 936.
27. Violari, A., Wiznia, A., Ndiweni, D. et al. Once daily (QD) emtricitabine (FTC) with other antiretroviral agents (ART) in HIV-infected pediatric patients at 48 weeks. XV Int AIDS Conf (July 11-16, Bangkok) 2004, Abstr. 4431.
28. Shiftman, M.L., Ng, T.M., Drastev, Z. et al. A double-blind, placebo-controlled trial of emtricitabine (FTC, Emtriva) administered once-daily for treatment of chronic hepatitis B virus (HBV) infection. Hepatology 2004, 40(4 Suppl. 1): 172A.
29. Sykes, A., Wakeford, C., Rousseau, F., Rigney, A., Mondou, E. Antiviral efficacy and rate of development of resistance in patients treated 1 year for chronic HBV infection with FTC. 9th Conf Retroviruses and Opportunistic Infections (Feb 24-28, Seattle) 2002, Abstr. M55e.
30. Mommeja Marin, H., Leung, N., Gish, R. et al. Antiviral activity and incidence of resistance after treatment for two years with emtricitabine in patients with chronic hepatitis B. 42nd Interscience Conf Antimicrob Agents Chemother (Sept 27-30, San Diego) 2002, Abstr. V-239.
31. Raffi, F., Snow, A., Borroto-Esoda, K. et al. Anti-HBV activity of emtricitabine (FTC) in patients co-infected with HIV and hepatitis B virus. 2nd Int AIDS Soc Conf HIV Pathogenesis and Treatment (July 13-16, Paris) 2003, Abstr. 215.
32. Benson, C., Sanne, I., van der Horst, C. et al. Long-term safety profile of emtricitabine (FTC) in HIV-1 infected adults. 41st Interscience Conf Antimicrob Agents Chemother (Sept 22-25, Chicago) 2001, Abstr. I-1931.
33. Mondou, E., Quinn, J.B., Shaw, A., Hinkle, J., Adda, N., Rousseau, F. Incidence of skin discoloration across phase 3 clinical trials of emtricitabine (FTC). XV Int AIDS Conf (July 11-16, Bangkok) 2004, Abstr. WePeB5916.
34. Bartlett, J. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor. 8th Conf Retroviruses Opportunistic Infections (Feb 4-8, Chicago) 2001, Abstr. 19.
35. Powderly, W., Cahn, P., Raffi, F. et al. Lipid abnormalities and body habitus in a double-blind, randomized, controlled trial comparing emtricitabine to stavudine in HIV+ ART-naive patients. 11th Conf Retroviruses Opportunistic Infections (Feb 8-11, San Francisco) 2004, Abstr. 717.